154 related articles for article (PubMed ID: 31199171)
1. Comparison of the inhibitory effect of ketoconazole, voriconazole, fluconazole, and itraconazole on the pharmacokinetics of bosentan and its corresponding active metabolite hydroxy bosentan in rats.
Chen M; Zhang X; Chen Y; Sun W; Wang Z; Huang C; Hu G; Chen R
Xenobiotica; 2020 Mar; 50(3):280-287. PubMed ID: 31199171
[TBL] [Abstract][Full Text] [Related]
2. Differential effects of ketoconazole, itraconazole and voriconazole on the pharmacokinetics of imatinib and its main metabolite GCP74588 in rat.
Lin G; Wang C; Qiu X; Wang Z; Han A; Xu T; Kan X; Hu G
Drug Dev Ind Pharm; 2014 Dec; 40(12):1616-22. PubMed ID: 24053419
[TBL] [Abstract][Full Text] [Related]
3. Effects of ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of apatinib in rats.
Lou D; Cui X; Bao SS; Sun W; Pan WH; Chen MC; Dong YY; Hu GX; Chen RJ; Wang Z
Drug Dev Ind Pharm; 2019 Apr; 45(4):689-693. PubMed ID: 30632818
[TBL] [Abstract][Full Text] [Related]
4. Voriconazole against fluconazole-susceptible and resistant candida isolates: in-vitro efficacy compared with that of itraconazole and ketoconazole.
Nguyen MH; Yu CY
J Antimicrob Chemother; 1998 Aug; 42(2):253-6. PubMed ID: 9738846
[TBL] [Abstract][Full Text] [Related]
5. Interactions of azole antifungal agents with the human breast cancer resistance protein (BCRP).
Gupta A; Unadkat JD; Mao Q
J Pharm Sci; 2007 Dec; 96(12):3226-35. PubMed ID: 17518356
[TBL] [Abstract][Full Text] [Related]
6. Effects of the CYP3A inhibitors, voriconazole, itraconazole, and fluconazole on the pharmacokinetics of osimertinib in rats.
Lou Y; Song F; Cheng M; Hu Y; Chai Y; Hu Q; Wang Q; Zhou H; Bao M; Gu J; Zhang Y
PeerJ; 2023; 11():e15844. PubMed ID: 37581117
[TBL] [Abstract][Full Text] [Related]
7. Inhibitory effect of isavuconazole, ketoconazole, and voriconazole on the pharmacokinetics of methadone in vivo and in vitro.
Shen L; Wang J; Yi Y; Ye C; Wang R; Xia G; Yu C; Tu F; Xu J; Zheng Z
Drug Test Anal; 2019 Apr; 11(4):595-600. PubMed ID: 30370647
[TBL] [Abstract][Full Text] [Related]
8. Inhibitory effect of ketoconazole and voriconazole on the pharmacokinetics of carvedilol in rats.
Wang L; Wang S; Chen M; Chen X; Lin Y; Hu X; Huang X; Li X; Hu G
Drug Dev Ind Pharm; 2015; 41(10):1661-6. PubMed ID: 25417773
[TBL] [Abstract][Full Text] [Related]
9. [Drug-drug interaction of antifungal drugs].
Niwa T; Shiraga T; Takagi A
Yakugaku Zasshi; 2005 Oct; 125(10):795-805. PubMed ID: 16205037
[TBL] [Abstract][Full Text] [Related]
10. Predicting the Effects of Different Triazole Antifungal Agents on the Pharmacokinetics of Tamoxifen.
Chen L; Zhu L; Li M; Li N; Qi F; Wang N
AAPS PharmSciTech; 2019 Jan; 20(1):24. PubMed ID: 30604153
[TBL] [Abstract][Full Text] [Related]
11. Effects of CYP3A inhibitors ketoconazole, voriconazole, and itraconazole on the pharmacokinetics of sunitinib and its main metabolite in rats.
Wang J; Cui X; Cheng C; Wang Y; Sun W; Huang CK; Chen RJ; Wang Z
Chem Biol Interact; 2021 Apr; 338():109426. PubMed ID: 33617800
[TBL] [Abstract][Full Text] [Related]
12. Conazoles.
Heeres J; Meerpoel L; Lewi P
Molecules; 2010 Jun; 15(6):4129-88. PubMed ID: 20657432
[TBL] [Abstract][Full Text] [Related]
13. The Influence of Different Triazole Antifungal Agents on the Pharmacokinetics of Cyclophosphamide.
Cai T; Liao Y; Chen Z; Zhu Y; Qiu X
Ann Pharmacother; 2020 Jul; 54(7):676-683. PubMed ID: 31893943
[No Abstract] [Full Text] [Related]
14. In vitro susceptibility of fluconazole-susceptible and -resistant isolates of Malassezia pachydermatis against azoles.
Jesus FP; Lautert C; Zanette RA; Mahl DL; Azevedo MI; Machado ML; Dutra V; Botton SA; Alves SH; Santurio JM
Vet Microbiol; 2011 Aug; 152(1-2):161-4. PubMed ID: 21658868
[TBL] [Abstract][Full Text] [Related]
15. In vitro susceptibility of Candida spp. to fluconazole, itraconazole and voriconazole and the correlation between triazoles susceptibility: Results from a five-year study.
Lei J; Xu J; Wang T
J Mycol Med; 2018 Jun; 28(2):310-313. PubMed ID: 29685520
[TBL] [Abstract][Full Text] [Related]
16. Inhibitory effects of voriconazole, itraconazole and fluconazole on the pharmacokinetic profiles of ivosidenib in rats by UHPLC-MS/MS.
Xie S; Ye L; Ye X; Lin G; Xu RA
J Pharm Biomed Anal; 2020 Aug; 187():113353. PubMed ID: 32417565
[TBL] [Abstract][Full Text] [Related]
17. Antifungal activities of azole agents against the Malassezia species.
Miranda KC; de Araujo CR; Costa CR; Passos XS; de Fátima Lisboa Fernandes O; do Rosário Rodrigues Silva M
Int J Antimicrob Agents; 2007 Mar; 29(3):281-4. PubMed ID: 17223320
[TBL] [Abstract][Full Text] [Related]
18. Clinically significant azole cross-resistance in Candida isolates from HIV-positive patients with oral candidosis.
Cartledge JD; Midgley J; Gazzard BG
AIDS; 1997 Dec; 11(15):1839-44. PubMed ID: 9412702
[TBL] [Abstract][Full Text] [Related]
19. In vitro investigation of antifungal activities of phenotypic variation Candida albicans strains against fluconazole, itraconazole and voriconazole.
Cetinkaya Z; Kiraz N
Nihon Ishinkin Gakkai Zasshi; 2005; 46(3):197-201. PubMed ID: 16094296
[TBL] [Abstract][Full Text] [Related]
20. History of the development of azole derivatives.
Maertens JA
Clin Microbiol Infect; 2004 Mar; 10 Suppl 1():1-10. PubMed ID: 14748798
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
